Kailera Therapeutics (KLRA) officer receives 175,000 stock options at $23.30 strike
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $23.30 per share and expire on July 6, 2036.
These options vest as to 25% of the underlying shares on June 29, 2027 and then in 36 substantially equal monthly installments, subject to her continued service. Following this grant, she holds stock options exercisable for 175,000 shares directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Tregoning Kathleen
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 175,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 175,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 175,000 options
Exercise price: $23.30 per share
Expiration date: July 6, 2036
+3 more
6 metrics
Option grant size
175,000 options
Grant covering 175,000 underlying common shares
Exercise price
$23.30 per share
Stock option exercise price
Expiration date
July 6, 2036
Option expiration
Initial vesting tranche
25% of shares
Vests on June 29, 2027
Monthly vesting installments
36 installments
Remaining options vest monthly after June 29, 2027
Options held after grant
175,000 options
Total stock options following transaction
Key Terms
Stock Option (right to buy), exercise price, expiration date, vest and become exercisable
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 23.3000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-06T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest and become exercisable financial
"The options vest and become exercisable as to 25% of the underlying shares"
FAQ
What did Kathleen Tregoning acquire in this Form 4 for KLRA?
She received a grant of stock options for 175,000 shares of Kailera Therapeutics common stock. These are compensation-related options, not open-market purchases, and give her the right to buy shares at a fixed exercise price.
What is the exercise price of the new KLRA stock options?
The options have an exercise price of $23.30 per share. This is the price at which Kathleen Tregoning can purchase Kailera Therapeutics common stock if and when the options become vested and she chooses to exercise them.
How do the newly granted KLRA options vest for Kathleen Tregoning?
The options vest as to 25% of the underlying shares on June 29, 2027. The remaining shares vest in 36 substantially equal monthly installments, conditioned on her continued service through each vesting date.
When do Kathleen Tregoning’s KLRA stock options expire?
The stock options expire on July 6, 2036. After that date, any unexercised portion of the 175,000-share grant can no longer be used to purchase Kailera Therapeutics common stock at the stated exercise price.
How many KLRA stock options does Kathleen Tregoning hold after this transaction?
After this grant, she holds stock options for 175,000 underlying shares directly. This Form 4 reflects a compensation-related award rather than a sale or open-market purchase of Kailera Therapeutics stock.